PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder TreatmentsGlobeNewsWire • 03/13/24
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial DataGlobeNewsWire • 11/17/23
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business UpdateAccesswire • 11/15/23
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed JournalAccesswire • 11/07/23
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)GlobeNewsWire • 11/02/23
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101GlobeNewsWire • 10/31/23
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for PublicationGlobeNewsWire • 10/26/23
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial DataAccesswire • 10/26/23
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/30/23
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 08/09/23
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 StudyMCAP MediaWire • 08/08/23
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301GlobeNewsWire • 07/24/23
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLCGlobeNewsWire • 07/06/23